Sonni, Ida http://orcid.org/0000-0002-8802-7704
Lee-Felker, Stephanie
Memarzadeh, Sanaz
Quinn, Molly M.
Mona, Christine E.
Lückerath, Katharina
Czernin, Johannes
Calais, Jeremie
Article History
Received: 6 May 2020
Accepted: 29 June 2020
First Online: 10 July 2020
Compliance with ethical standards
:
: Johannes Czernin is a founder, board member, and holds equity in Sofie Biosciences and Trethera Therapeutics. Intellectual property patented by the University of California is licensed to Sofie Biosciences and Trethera Therapeutics. Johannes Czernin serves on the medical advisory board of Actinium and is a member of the VISION trial steering committee, a clinical trial sponsored by Endocyte. Johannes Czernin is the recipient of a grant from the US Department of Energy (DESC0012353), from the Prostate Cancer Foundation (2017 and 2019 Challenge Awards, 17CHAL02 19CHAL02), and from the Johnson Comprehensive Cancer Center NIHNCI Cancer Center Support Grant (P30 CA016042).Jeremie Calais is the recipient of grants from the ERF-SNMMI (2019–2021 Molecular Imaging Research Grant for Junior Academic Faculty), the Philippe Foundation Inc. (NY, USA), and the ARC Foundation (France) (International Mobility Award SAE20160604150).Jeremie Calais is a consultant for Blue Earth Diagnostics, Curium Pharma, GE Healthcare, Janssen Pharmaceuticals, Progenics Radiopharmaceuticals, Radiomedix, and Telix Pharmaceuticals, outside of the submitted work.All other co-authors have no conflict of interest.
: All procedures performed in this study were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Written and oral informed consent was provided by the patient involved in this study.